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Abstract
The metabolic enzyme fatty acid synthase (FASN) is responsible for the endogenous synthesis of palmitate, a saturated
long-chain fatty acid. In contrast to most normal tissues, a variety of human cancers overexpress FASN. One such cancer is
cutaneous melanoma, in which the level of FASN expression is associated with tumor invasion and poor prognosis. We
previously reported that two FASN inhibitors, cerulenin and orlistat, induce apoptosis in B16-F10 mouse melanoma cells via
the intrinsic apoptosis pathway. Here, we investigated the effects of these inhibitors on non-tumorigenic melan-a cells.
Cerulenin and orlistat treatments were found to induce apoptosis and decrease cell proliferation, in addition to inducing the
release of mitochondrial cytochrome c and activating caspases-9 and -3. Transfection with FASN siRNA did not result in
apoptosis. Mass spectrometry analysis demonstrated that treatment with the FASN inhibitors did not alter either the
mitochondrial free fatty acid content or composition. This result suggests that cerulenin- and orlistat-induced apoptosis
events are independent of FASN inhibition. Analysis of the energy-linked functions of melan-a mitochondria demonstrated
the inhibition of respiration, followed by a significant decrease in mitochondrial membrane potential (DYm) and the
stimulation of superoxide anion generation. The inhibition of NADH-linked substrate oxidation was approximately 40% and
61% for cerulenin and orlistat treatments, respectively, and the inhibition of succinate oxidation was approximately 46%
and 52%, respectively. In contrast, no significant inhibition occurred when respiration was supported by the complex IV
substrate N,N,N9,N9-tetramethyl-p-phenylenediamine (TMPD). The protection conferred by the free radical scavenger N-
acetyl-cysteine indicates that the FASN inhibitors induced apoptosis through an oxidative stress-associated mechanism. In
combination, the present results demonstrate that cerulenin and orlistat induce apoptosis in non-tumorigenic cells via
mitochondrial dysfunction, independent of FASN inhibition.
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Introduction
The metabolic enzyme fatty acid synthase (FASN) is responsible
for the production of saturated fatty acids, such as palmitate,
through the condensation of acetyl-CoA and malonyl-CoA [1–7].
FASN products are used in the formation of cell membranes [8]
and are responsible for a significant number of functions in the
body, acting primarily as intracellular messengers and energy
stores [9]. In most normal tissues, the expression and activity of
FASN are low or absent; exceptions include instances where
lipogenesis is necessary, such as in the liver, adipose tissue, breast
tissue during lactation, endometrium during the proliferative
phase and the lungs of newborns [2,3,10,11]. In contrast, high
FASN activity is found in several neoplasias that occur in breast,
ovarian, prostate, thyroid, lung, stomach, pancreas, colon,
esophagus, mouth and bladder tissues, as well as soft tissue
sarcomas and melanoma [10,12–33]. Further, increased FASN
expression in malignant tumors is associated with a poor prognosis
[4,13,14,16,17,21,24,28,29,33–38].
FASN inhibition reduces cell proliferation and induces apop-
tosis in vitro and decreases the size of prostate, ovarian and breast
cancer xenografts [39–41]. The biological mechanisms responsible
for FASN inhibition-induced apoptosis remain unclear. The
extrinsic apoptosis pathway, which is triggered by death domains,
was described after siRNA silencing of FASN in breast cancer cells
caused the accumulation of malonyl-CoA and ceramide [42,43].
Mitochondrial involvement in apoptosis, as evidenced by in-
creased levels of the pro-apoptotic protein Bax and the release of
cytochrome c, has been found in several tumor cell lines, including
neuroblastoma, melanoma, colon carcinoma, breast cancer and
skin carcinoma, following pharmacological FASN inhibition
[37,44]. Despite the fact that the expression of a dominant-
negative mutant p53 increased the sensitivity of colon carcinoma
cells to FASN inhibitors [45], FASN inhibition-induced apoptosis
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was described as a p53-independent process [44]. We recently
showed that the inhibition of FASN activity with orlistat
significantly impaired lipid synthesis, reduced proliferation and
promoted apoptosis in the mouse metastatic melanoma cell line
B16-F10 [46,47]; additionally, similar treatment reduced experi-
mental metastases and angiogenesis in B16-F10 melanomas [48].
We showed that FASN inhibition activates the intrinsic apoptotic
pathway, as evidenced by the release of cytochrome c and the
activation of caspases-9 and -3; this activation is preceded by
increased production of reactive oxygen species and elevated
cytosolic calcium concentrations in these melanoma cells [47].
Orlistat treatment of B16-F10 cells also resulted in significant
changes in the mitochondrial free fatty acid (FFA) composition, as
demonstrated by electrospray ionization mass spectrometry (ESI-
MS) [49].
Although several studies suggest that normal cells are more
resistant to the cytotoxic action of FASN inhibitors [40,43,50–52],
cerulenin and orlistat significantly reduced the proliferation of
normal gingival fibroblasts and endothelial cells [26,53,54]. Here,
we show that similar to B16-F10 cells, non-tumorigenic melan-a
cells exhibit reduced proliferation and undergo apoptosis through
the release of cytochrome c and the activation of caspases-9 and -3
when treated with FASN inhibitors. The effect of these FASN
inhibitors on the non-tumorigenic cell line used here involves the
inhibition of mitochondrial respiration but does not alter the FFA
content of these cells.
Materials and Methods
Cell Culture and Reagents
Melan-a cells, the first known line of non-tumorigenic mouse
melanocytes and a normal counterpart to melanoma cells [55],
were obtained from Profa. Miriam Galvonas Jasiulionis (Uni-
versidade Federal de Sa˜o Paulo, Sa˜o Paulo, Brazil) and were
cultured in RPMI-1640 medium (Vitrocell, Brazil) supplemented
with 5% fetal bovine serum (Vitrocell), 200 nM 12-o-tetradecanoyl
phorbol-13-acetate (TPA, Sigma-Aldrich, St. Louis, MO, USA),
100 mg/ml gentamycin (Vitrocell), 100 IU/ml penicillin (Vitro-
cell) and 100 mg/ml streptomycin (Vitrocell) at 37uC in a
humidified atmosphere with 5% CO2. To block FASN activity,
either cerulenin (Sigma-Aldrich, USA) or orlistat (Roche, Swit-
zerland) was added to the culture medium at the concentration
specified in the figure legends. The IC50 for b-keto-acyl-ACP
synthase inhibition by cerulenin is 1.5 mM, and the Ki for FASN
inhibition by orlistat is 0.3060.09 mM [56]. Orlistat was extracted
from Xenical capsules as previously described [57]. The equivalent
concentrations of cerulenin and orlistat solvents, 0.025% DMSO
and 0.012% ethanol (EtOH), respectively, were present under
control conditions. Cells treated with cerulenin showed faster
degeneration than cells treated with orlistat; for this reason
different treatment durations were used for cerulenin (6–24 h) and
orlistat (24–48 h).
The non-tumorigenic HaCaT cell line, which was derived from
human keratinocytes, was purchased from Cell Line Service (CLS,
Heidelberg, Germany). HaCaT cells were grown in a high-glucose
DMEM culture medium (Vitrocell) supplemented with 10% fetal
bovine serum and antibiotics, in the same manner as that
described for the melan-a cells.
Determination of Cell Viability and Proliferation
To determine the antiproliferative and cytotoxic effects of
cerulenin and orlistat, the cells were stained with 0.1% trypan blue
and then counted in a Neubauer chamber, as previously described
[47]. Cell viability was determined by excluding the stained cells,
as well as by using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide assay (MTT, Sigma). Briefly, melan-a cells
were plated in 6-well culture plates (2.5–6.56104 cells per well),
and after 24 h, the medium was replaced with fresh medium that
contained the FASN inhibitors. After an additional 24 or 48 h, the
cells were incubated with 2.5 mg/ml MTT for 4 h at 37uC in a
5% CO2 incubator. Then, the medium was removed, and 1 ml of
absolute ethanol was added to each well for complete solubiliza-
tion of the generated formazan. The contents were subsequently
transferred to 96-well plates, and the absorbance was determined
at 540 nm with the aid of a microplate reader (Bio-Rad, USA). In
this work, cell viability is expressed as the percentage of viable cells
relative to the controls.
Analysis of Cell Death and Cell Cycle
The samples were analyzed in a FACSCalibur flow cytometer
(BD Biosciences, Franklin Lakes, NJ, USA) equipped with an
argon laser and Cell-Quest software (version 4.1). Between seven
and ten thousand events were acquired per sample. Melan-a
populations were identified based on their light-scattering charac-
teristics by enclosing the samples in electronic gates and analyzing
for the intensity of the fluorescent probe signal.
For the cell death analysis, melan-a cells (106) were washed with
PBS and resuspended in binding buffer (10 mM HEPES pH 7.4,
150 mM NaCl, 5 mM KCl, 1 mM MgCl2 and 1.8 mM CaCl2)
containing annexin V-FITC (1:500, Invitrogen, USA) and 7-AAD
(20 mg/ml, 7-amino-actinomycin D, Molecular Probes, USA), as
previously described [47]. Cell apoptosis was quantified by flow
cytometry as the number of annexin V-FITC-positive and 7-AAD-
negative cells, and necrosis was quantified as the number of 7-
AAD-positive and annexin V-FITC-negative cells, both divided by
the total number of cells.
Cell cycle analyses were performed as previously described
[46,47]. Melan-a cells were seeded in 6-well culture plates (2.5–
6.56104 cells). After 24 h, the medium was replaced with serum-
free medium, and the cells were incubated for an additional 24 h.
The medium was replaced with fresh medium containing serum
and the respective FASN inhibitor, and the cells were incubated
for an additional 24 or 48 h, then harvested and fixed in cold 70%
ethanol. The cells were then washed in PBS, treated with 10 mg/
ml RNAse for 1 h at 37uC and stained with 50 mg/ml propidium
iodide (Sigma) for 2 h at 41uC. The distribution of cells in the cell
cycle was analyzed by flow cytometry. The cell cycle phases were
analyzed using ModFit LTTM (Verity Software House, USA).
Measurement of ROS
Following treatment with cerulenin or orlistat for 24 or 48 h 106
viable cells were incubated with 5 mM MitoSOX (Molecular
Probes) at 37uC for 10 min to detect mitochondrial superoxide
production [58]. The ROS levels were analyzed using a
spectrofluorometer (Hitachi, model F-4500, Tokyo, Japan) oper-
ating at excitation and emission wavelengths of 510 and 580 nm,
respectively, with slits widths of 5 and 10 nm, as previously
described [47,59].
Detection of Caspase-3 Activation
Caspase-3 activation was assessed by incubating 106 cells with
FITC-DEVD-FMK (1:300, Calbiochem, USA) in serum-free
medium for 40 min at 37uC in a humidified atmosphere with
5% CO2. After a wash step was performed according to the
manufacturer’s instructions, the cells were resuspended in the
same medium and analyzed by flow cytometry, as previously
described [46].
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Figure 1. Cerulenin and orlistat reduce cell viability and induce apoptosis in the melan-a cell line. Melan-a cells were treated with
increasing concentrations of cerulenin or orlistat for 24 or 48 h, respectively; cell viability was determined using trypan blue (A and B) or MTT assays
(C and D), and apoptosis was determined by flow cytometry after Annexin V staining (E and F). The values represent the mean 6 s.e.m of at least
three independent experiments. *Significantly different from the respective control at p,0.05.
doi:10.1371/journal.pone.0101060.g001
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Detection of Caspases-9 and -8 Activities
Cells (36106 cells) were resuspended in 0.2 ml of chilled lysis
buffer (20 mM HEPES pH 7.5, 10 mM KCl, 250 mM sucrose,
2 mM MgCl and 1 mM EDTA) containing 0.5 mM DTT. The
cell suspensions were sonicated (Mosonix Sonicator S-3000, New
Highway Farmingdale, USA) and frozen at 280uC. The cell
lysates were thawed and centrifuged at 15,000 g for 30 min, and
the supernatants were added to 0.2 ml of reaction buffer (25 mM
HEPES pH 7.5, 10% sucrose and 0.1% CHAPS) containing
10 mM DTT. The reactions were initiated by the addition of the
caspase-8 or 29 substrates, 0.1 mM Ac-LETD-AFC (Sigma) or
0.2 mM LEHD-pnitroanilide (Calbiochem), respectively, and
were incubated for 1.5 h at 37uC, as previously described [47].
Caspase-8 activity was determined by measuring the fluorescence
of free AFC using a Hitachi F4500 spectrofluorometer (Hitachi
High-Tech, Japan), with excitation and emission wavelengths of
400 and 505 nm, respectively, and slit widths of 5.0 nm. Melan-a
cells treated for 20 h with 1.25 mg/ml cycloheximide (Sigma) and
10 nM tumor necrosis factor alpha (TNFa, Peprotech, USA) were
used as positive controls. Caspase-9 activity was determined by
measuring the absorbance of free p-nitroanilide using a Varian
Cary 50 spectrophotometer (Biocompare, USA) at 405 nm.
Detection of Cytochrome c Release
After the cells were treated with cerulenin or orlistat for 12 or
24 h, the release of mitochondrial cytochrome c was detected by
flow cytometry [60]. Briefly, 106 cells were washed with PBS,
resuspended in 1 ml of mitochondrial medium (125 mM sucrose,
65 mM KCl, 10 mM HEPES buffer pH 7.2, 0.5 mM EGTA,
1 mMMgCl2 and 2 mM KH2PO4) supplemented with 1% mix of
protease inhibitors and 1 mM phenylmethylsulfonyl fluoride and
then permeabilized with 0.0001% digitonin. Pellets were resus-
pended in 0.5 ml of 4% paraformaldehyde in PBS and incubated
for 20 min at room temperature. After two washes with PBS, the
cells were incubated in 0.5 ml of labeling medium (2% fetal bovine
serum, 0.2% sodium azide and 0.5% Triton X-100 in PBS) for
15 min, centrifuged at 3,000 g for 5 min and then incubated with
an anti-cytochrome c antibody (1:500, 6 H2.B4, Promega, USA)
at 4uC for 1 h. The cells were then washed twice in the same
medium and incubated with an anti-mouse-FITC antibody (1:200,
Vector Laboratories, USA) at 4uC for 1 h. The cells were washed
once more as described above, resuspended in PBS and analyzed
by flow cytometry as described elsewhere [60].
Assessment of Mitochondrial Membrane Potential
(DYm)
The DYm in the digitonin-permeabilized melan-a cells was
estimated by changes in Safranin O fluorescence [61], as recorded
using a spectrofluorometer (Hitachi, model F-4500, Tokyo, Japan)
operated at excitation and emission wavelengths of 495 and
586 nm, respectively, with slits widths of 5 nm. Melan-a cells were
treated with 22 mM cerulenin for 6 h or with 30 mM orlistat for
24 h. Approximately 26106 viable cells were permeabilized with
15 mM digitonin in 2 ml of reaction medium containing 125 mM
sucrose, 65 mM KCl, 10 mM HEPES, 1 mM MgCl2, 65 mM
Tris-HCl (pH 7.2), 2.5 mM Na2HPO4, 50 mM EGTA, 5 mM
succinate, 0.01% BSA and 5 mM Safranin O; then, the reactions
were incubated at 37uC while stirring [59,62–64].
Cellular Respiration
Following either 24 h of treatment with 22 mM cerulenin or
48 h of treatment with 30 mM orlistat, the consumption of oxygen
by the melan-a cells was measured using a closed-chamber high-
resolution respirometry Oroboros (Innsbruck, Austria) equipped
with a magnetic stirrer and temperature control set at 37uC [65–
67]. Approximately 26106 viable cells were added to 2 ml of
reaction medium containing 125 mM sucrose, 65 mM KCl,
10 mM HEPES, 2.0 mM K2HPO4, 1.0 mM MgCl2 (pH 7.2);
50 mM EGTA, 0.01% BSA and NADH-linked substrates (2.0 mM
malate, 1.0 mM a-ketoglutarate, 1.0 mM pyruvate and 1.0 mM
glutamate). Then, the melan-a cells were permeabilized by the
addition of 15 mM digitonin, and the oxidative phosphorylation
and mitochondrial respiratory activity were analyzed by the
sequential addition of 300 mM ADP, 2 mg/ml oligomycin,
100 nM carbonylcyanide p-trifluoromethoxyphenylhydrazone
(FCCP), 5 mM succinate, 0.5 mM antimycin and 200 mM
N,N,N9,N9-tetramethyl-p-phenylenediamine (TMPD) with 2 mM
ascorbate. The data were determined using the device software.
Citrate Synthase Activity
Citrate synthase activity in the cell suspension was analyzed by
spectrophotometry based on the conversion of oxaloacetate and
acetyl-CoA to citrate and SH-CoA. This reaction is catalyzed by
citrate synthase and was monitored by measuring the colorimetric
product thionitrobenzoic acid [47]. Cytosolic fractions were
incubated at 37uC in a buffer containing 50 mM Tris–HCl
Figure 2. FASN inhibitors blocked cell cycle progression in
non-tumorigenic cells. Melan-a cells were treated with 22 mM
cerulenin or 30 mM orlistat for 24 or 36 h, respectively. Then, the
percentage of cells in each phase of the cell cycle was determined by
flow cytometry after PI staining (A). Western blot analysis of protein
extracts prepared from cerulenin- and orlistat-treated melan-a cells
revealed the accumulation of the p21WAF1/Cip1 tumor suppressor
protein (B). The data were normalized using beta-actin as a loading
control. The values represent the mean 6 s.e.m of at least five
independent experiments. *Significantly different from the respective
control at p,0.05.
doi:10.1371/journal.pone.0101060.g002
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(pH 8.0), 0.1% Triton X-100, 250 mM oxaloacetate, 50 mM
acetyl-CoA and 100 mM 5,50-dithiobis-(2-nitrobenzoic acid).
The increase in absorbance at 412 nm was recorded over 8 min.
RNA Interference (RNAi)-Mediated Silencing of FASN
Expression
Twenty-five-mer RNA molecules were chemically synthesized,
annealed and purified by the manufacturer (Stealth RNAi,
Invitrogen). Three sequences targeting Mus musculus FASN
(NM_00798) were used, corresponding to nucleotides 940–964
(50-CAATGATGGCCAACCGGCTCTCTTT-30), 3408–3432
(50-TGGGAAGACCCGAACTCCAAGTTAT-30) and 5841–
5865 (50-CCTCTGGGCATGGCTATCTTCTTGA-30), as pre-
viously described [46]. Melan-a cells grown to 50% confluence
were transfected with 200 nM of a mixture containing equal parts
of the FASN siRNAs using a liposome method according to the
manufacturer’s instructions (Lipofectamine 2000, 2 mg/ml, Invi-
trogen). Negative control cells were transfected with equimolar
concentrations of a nonspecific control oligo (Stealth RNAi
Negative Control Duplexes, Medium GC Duplex, Invitrogen).
Transfections were performed in 35-mm2 dishes, and after 48 h,
the cells were collected to assess FASN knockdown and to detect
cell death. FASN knockdown was confirmed by Western blot
analysis using approximately 40 mg of the protein lysates and
antibodies against FASN (BD Biosciences, 1:3000) or beta-actin
(AC-15, Sigma, 1:40 000) as a loading control. The reactions were
developed with an enhanced chemiluminescence detection system
(ECL detection kit, Amersham Pharmacia Biotech, USA) accord-
ing to the manufacturer’s instructions.
Electrospray Ionization Mass Spectrometry (ESI-MS)
ESI-MS was used to analyze the melan-a mitochondria, as
previously described [49], with few modifications. After the
mitochondria were extracted, the total protein content was
quantified using the Bradford method. Lipid extraction was
performed as described by Bligh and Dyer (1959) [68]. The
mitochondria-containing pellets were resuspended in 0.1 ml of
ultrapure H2O, and 0.5 ml of a solution of methanol/toluene (7:3
v/v) and 0.05 ml of a methanol solution of ammonia (0.1% v/v)
were added to each sample. This diluted solution was then directly
infused according to the following protocol. A total of 16 samples
was analyzed, 4 from the control and 4 from the treated cells for
each FASN inhibitor.
Lipid analyses were performed in negative mode using an ESI
Q-TOF Premier (Waters) coupled with a nanoelectrospray source
introduced via direct injection, performed at a flow rate of 10 mL/
min and using a Harvard Apparatus pump. The nanoelectrospray
voltage was set to 2.5 kV; the cone voltage, to 40 V; the source
temperature, to 120uC; the desolvatation temperature, to 200uC;
and the collision energy, to 10 V. The instrument was operated in
MS continuum mode, and data were acquired from m/z 50–1.000
with a scan rate of 1 s and an interscan delay of 0.1 s. The data
were analyzed using the Masslynx 4.1 software package. The
spectra were accumulated over 6 s in the region with flow rate
stability. The spectra were smoothed (263 channels, Savitzky
Golay smooth), and the mass centroid values were obtained using
80% of the peak top and the minimum peak width at half-height of
4 channels. Principal component analysis was performed using the
MetaboAnalyst software. Data were autoscaled for principal
component analysis (PCA) and partial least square discriminant
analysis (PLS-DA). The analyses were performed using the
MetaboAnalyst online platform [69,70], supported by the use of
the Piroeutte (v. 4.0, Infometrix, Inc.) software.
Statistical Analysis
The results from at least three independent experiments, each
performed in duplicate or triplicate, are displayed as the mean 6
s.e.m. Comparisons between the groups were performed using
One-Way Analysis of Variance with Tukey’s post-hoc analysis.
The level of significance was set at p,0.05. All data were analyzed
using SigmaStat software, version 3.5 (Systat Software, USA).
Results
FASN inhibitors decrease melan-a cell viability and
proliferation and induce cell death in a dose-dependent
manner
The viability of melan-a cells was significantly reduced after
treatment with cerulenin or orlistat (Figure 1). The decrease in
cell viability estimated by the trypan blue or MTT (Panels A–D)
assays was higher than the apoptotic rate (Panels E–F), possibly
due to the higher sensitivity of the test used to estimate cell viability
[71]. Death in the melan-a cell line occurred mainly by apoptosis,
as we previously demonstrated for the B16-F10 melanoma cells
[47], while the necrosis rates remained unchanged by these
treatments (DMSO: 2.460.5%, 22 mM cerulenin: 2.460.5%;
EtOH: 1.560.8%; 30 mM orlistat: 2.460.4%). No significant
effect of the vehicles (EtOH and DMSO) on cell viability and
apoptosis rate was observed (results not shown).
Cell cycle analysis was performed to verify the effects of both
FASN inhibitors on cell proliferation. After 24 h of serum
starvation, approximately 80% of the melan-a cells were in the
G0/G1 phase (data not shown). The cerulenin- and orlistat-treated
melan-a cells demonstrated reductions of 25% and 42% in S
phase, respectively, when compared to the controls (Figure 2 A).
Cell cycle arrest was confirmed by increased levels of the p21WAF1/
Cip1 tumor suppressor protein, as shown by Western blot analysis
(Figure 2 B). The treatment of melan-a cells with cerulenin and
orlistat increased p21WAF1/Cip1 levels by 1.4- and 3.4-fold,
respectively, compared to the control cells.
The FASN inhibitors were also tested in another non-
tumorigenic cell line, HaCaT, which is derived from normal
keratinocytes. Similar to the melan-a cells, cerulenin and orlistat
reduced the viability and proliferation of HaCaT and induced
apoptosis (Figure S1). The HaCaT cells were more resistant to
apoptosis than the melan-a cells, especially when treated with
cerulenin while the necrosis rates remained unchanged by these
treatments (DMSO: 0.2060.08%, 45 mM cerulenin: 1.9760.27%;
EtOH: 0.2060.06%; 300 mM orlistat: 1.6760.20%). The HaCaT
cells also showed lower levels of FASN protein when compared to
the melan-a cells, as verified by Western blot analysis (Figure S2).
Cell cycle analysis of the HaCaT cells after treatment with the
FASN inhibitors revealed a significant degree of cell cycle arrest.
Cerulenin and orlistat treatment increased the number of cells in
G0/G1 phase by 3- and 6-fold, respectively (Figure S3 A).
Treatment with the FASN inhibitors also increased the p21WAF/
Cip protein content by 1.3- or 35-fold when compared to the
respective controls (Figure S3 B).
Mitochondrial dysfunction participates in melan-a cell
death induced by FASN inhibitors
Recently, we demonstrated the release of mitochondrial
cytochrome c in the FASN inhibition-induced apoptosis of B16-
F10 melanoma tumor cells [47]. Because FASN inhibitors also
induced apoptosis in the melan-a cells (Figures 1 E and F), the
non-tumorigenic melanoma cell counterpart [55], the percentage
of cytochrome c released was also determined in these cells.
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Cerulenin and orlistat treatment for 12 and 24 h culminated in the
release of cytochrome c in the melan-a cells (16% and 12%,
respectively) (Figure 3 A), and this finding was accompanied by
the activation of caspase-3 (52% and 24%, respectively) (Figure 3
B) and caspase-9 (28% and 24%, respectively) (Figure 3 C). No
significant differences were found in caspase-8 activity (Figure 3
D). Pre-treatment with cyclosporin A, which is a classic inhibitor of
mitochondrial permeability transition, did not protect the melan-a
cells from cerulenin- or orlistat-induced apoptosis (Figure S4 A).
Apoptosis in the melan-a cells was also shown to be independent of
p53 activation, as pre-treatment with pifithrin-alpha (PFT), which is
a known synthetic inhibitor of p53 [72], did not prevent FASN
inhibitor-induced cell death (Figure S4 B).
In situ analysis of the energy-linked functions of melan-a
mitochondria indicated that treatment with the FASN inhibitors
decreased the DYm and inhibited respiration (Figures 4 and 5).
Digitonin-permeabilized melan-a cells showed the ability to
phosphorylate ADP, as illustrated by the carboxyatractyloside
(CAT) sensitive decrease in DYm (Figure 4, panels A and B,
black lines), while both the cerulenin and orlistat treatments
(Figure 4, panels A and B, green lines) resulted in significant
decreases in DYm and the inability of the mitochondria to
respond to the addition of ADP and CAT.
To gain a better understanding of the possible mechanism
involved in mitochondrial dysfunction, we analyzed the mito-
chondrial generation of superoxide in the melan-a cells. Figure 4C
shows a significant increase in mitochondrial superoxide produc-
tion when melan-a cells were incubated with either FASN
inhibitor. Incubation of the cells with the antioxidant N-
acetylcysteine (NAC) prevents the increased superoxide generation
promoted by these FASN inhibitors. Because mitochondria can be
both an important source and target of ROS [73], we then
analyzed the possible mitochondrial dysfunctions caused by ROS
attack. Therefore, the nature of the DYm decrease by FASN
inhibitors was assessed by measuring mitochondrial respiration
under both uncoupled or phosphorylating conditions using
NADH-linked substrates, succinate or the complex IV substrate
TMPD (Figure 5). The results presented in panels A and B show
that both cerulenin and orlistat resulted in a significant inhibition
of NADH-linked substrate-supported respiration. As expected, the
extent of the respiration inhibition was more significant at the
maximum rates (FCCP present). Panels C and D show the rates
of uncoupled succinate or TMPD-supported respiration, which
indicate a significant inhibition of succinate but not of TMPD
oxidation. Panel E provides evidence that the FASN inhibitors
did not alter the number or mass of mitochondria, as indicated by
the lack of an observable effect on citrate synthase activity.
Therefore, our results show that the FASN inhibitors activate
apoptosis in melan-a cells through a mechanism that involves the
inhibition of mitochondrial respiration.
To determine whether FASN inhibitor-induced cell death can
be prevented by ROS scavenging agents, further experiments were
conducted in the presence of N-acetyl cysteine (NAC). NAC
produces important metabolic products that control the cellular
Figure 3. Treatment of melan-a cells with FASN inhibitors leads to the release of mitochondrial cytochrome c and the activation of
caspases-3 and -9 but not -8. Melan-a cells were treated with 22 mM cerulenin or 30 mM orlistat for 12 or 24 h, respectively; then, the release of
cytochrome c was determined by flow cytometry (A). The cells were also treated with cerulenin or orlistat under the same conditions, and the
activation of caspase-3 was estimated using FITC-DEVD-FMK (B). The activities of caspase-9 and -8 (C and D) were determined as described in
Material and Methods. The values represent the mean 6 s.e.m of at least three independent experiments. *Significantly different from the respective
control at p,0.05.
doi:10.1371/journal.pone.0101060.g003
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redox state, protect cells against mitochondrial dysfunctions
associated with oxidative stress, and act as ROS scavengers [74–
77]. Melan-a cells were then incubated with 5 mM NAC for 1 h
prior to cerulenin or orlistat treatment. The results show that the
melan-a cell death induced by cerulenin and orlistat were inhibited
by 87% and 47%, respectively, in the presence of NAC (Figure 6,
A and B).
Cerulenin- and orlistat-induced apoptosis events in
melan-a type cells occur independently of FASN
inhibition
To determine whether the effects of cerulenin and orlistat on
cell viability, proliferation and mitochondrial function were related
to the actions of the respective agents on FASN, the enzymatic
activity of FASN was evaluated. Despite the detection of FASN
protein by Western blot analysis (Figure S2), the enzymatic
activity of FASN in melan-a cells was too low for quantification
using radioactive markers with higher sensitivity, such as [3H]-
water and [14C]-acetate (data not shown), as was previously
performed for B16-F10 melanoma cells [46]. These results were
supported by siRNA experiments that successfully down-regulated
FASN expression in melan-a cells by significantly reducing protein
levels (Figure 7 A) without a corresponding increase in apoptotic
rates (Figure 7 B).
ESI-MS was performed in melan-a cells to analyze the
mitochondrial FFA composition after treatment with the FASN
inhibitors. In contrast to what we observed in the melanoma B16-
F10 cells [49], the incubation of the non-tumorigenic cells with
Figure 4. FASN inhibitors result in decreased DYm and increased superoxide production in melan-a cells. Melan-a cells were treated
with 22 mM cerulenin or 30 mM orlistat for 6 or 24 h, respectively; then, approximately 26106 viable cells/ml were permeabilized with 15 mM
digitonin. DYm was estimated by Safranin fluorescence. The arrows indicate the addition of 15 mM digitonin, 100 mM ADP, 5 mM carboxyatractylo-
side (CAT) and 1 mM CCCP (A and B, representative of at least three independent experiments). Melan-a cells were also treated with 22 mM cerulenin
or 30 mM orlistat for 24 or 48 h, respectively and also incubated in the presence or absent of NAC; the cells were then washed and probed with 5 mM
MitoSOX (C). The values represent the mean6 s.e.m of four independent experiments. *Significantly different from the respective control at p,0.05.
#Significantly different from the respective condition in the absence of NAC at p,0.05.
doi:10.1371/journal.pone.0101060.g004
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cerulenin or orlistat did not significantly alter the FFA content
when principal component analysis (PCA) was applied to the ESI-
MS data. The relative concentration (%) of palmitic acid was not
significantly modified after treatment with the FASN inhibitors
(DMSO and cerulenin: 38.6 and 43.4%, respectively; EtOH and
orlistat: 41.6 and 39.0%, respectively). Additionally, non-signifi-
cant alterations were observed for the most abundant FFAs
detected, which include myristic acid (DMSO and cerulenin: 15.0
and 10.2%, ethanol and orlistat: 20.1 and 24.4%, respectively) and
stearic acid (DMSO and cerulenin: 26.6 and 31.8%, EtOH and
orlistat: 22.1 and 14.5%, respectively). Together, the ESI-MS and
RNAi results suggest that the effects of cerulenin and orlistat on
melan-a proliferation and viability are independent of their effects
on FASN levels and activity.
Figure 5. Treatment with FASN inhibitors promotes the inhibition of respiration in melan-a cells. Oxygen consumption by the melan-a
cells was measured after treatment for 24 h with 22 mM cerulenin (A) or for 48 h with 30 mM orlistat (B) using high-resolution respirometry
(Oroboros) in a closed chamber equipped with a magnetic stirrer and temperature control set to 37uC. Approximately 26106 viable cells/ml were
permeabilized with 15 mM of digitonin and then were added to 2 ml of reaction medium (described in Materials and Methods). Analyses of oxidative
phosphorylation and respiratory activity of the mitochondria were made by sequential additions of 300 mM ADP, 2 mg/ml oligomycin, 100 nM
carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP), 5 mM succinate, 0.5 mM antimycin and 200 mM N,N,N9,N9-tetramethyl-p-phenylene-
diamine (TMPD) with 2 mM ascorbate (A–D). The activity of citrate synthase was measured in melan-a cells after 24 or 48 h of treatment with 22 mM
cerulenin or 30 mM orlistat (E). The values represent the mean 6 s.e.m of at least four independent experiments. *Significantly different from the
respective control at p,0.05.
doi:10.1371/journal.pone.0101060.g005
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Discussion
FASN has been described as a possible target for chemotherapy
because its expression is low or absent in most normal tissues and,
in contrast, is high in a significant variety of human malignant
tumors, where FASN plays important roles in proliferation
[10,12,13,16,18–20,22–25,27,28,30–32]. As a result, FASN inhib-
itors are potential antitumor agents due to their ability to reduce
cell proliferation and induce apoptosis [44,47,57,78] without
apparent toxicity to normal tissues [50,51]. Although the role of
FASN in nonmalignant cells remains uncertain, it is known that
the FASN inhibitor cerulenin promotes a reduction in the
proliferation of normal fibroblasts in primary cultures [52,53],
and orlistat has been shown to have antiproliferative effects in
human umbilical vein endothelial cells (HUVEC) [26,48,54].
Here, we analyzed the mechanisms of toxicity of the FASN
inhibitors cerulenin and orlistat in cells derived from non-
tumorigenic mouse melanoblasts. When these melan-a cells were
incubated with FASN inhibitors, the cells underwent apoptosis and
exhibited a reduced proliferative rate (Figure 1), an increased
percentage of cells in G0/G1 phase (Figure 2 A) and an increased
level of p21WAF1/Cip1 tumor suppressor protein (Figure 2 B). We
also evaluated the effects of the FASN inhibitors on non-
tumorigenic HaCaT cells. Although these cells were more resistant
to apoptosis (Figure S1) than the melan-a cells (Figure 1), the
HaCaT cells underwent a significant cell cycle arrest (Figures
S3). These results are in agreement with data showing that FASN
inhibitors promote cell death and cell cycle arrest, along with the
increased expression of both p21WAF1/Cip1 and p53 in colon,
breast, gastrointestinal and human melanoma tumor cells [45,78–
80].
The increased number of annexin V-positive melan-a cells
(Figure 1 E and F), the release of cytochrome c (Figure 3 A) and
the activation of caspases-9 and -3 (Figure 3 B and C) are
compatible with the activation of the intrinsic apoptosis pathway
[81–83]. Similar results have been obtained with neuroblastoma,
breast cancer and melanoma cell lines [37,44,47]. This interpre-
tation is also supported by the lack of caspase-8 activation by the
FASN inhibitors, a result that excludes the extrinsic apoptosis
pathway in melan-a cell death [84]. In agreement with our results,
the exclusion of the extrinsic apoptosis pathway was previously
reported for breast tumor cells after FASN inhibition [42].
Additionally, the increased expression of p21WAF1/Cip1 (Figure 2
B and Figure S3 B) suggests that p53 was activated when melan-
a and HaCaT cells were treated with cerulenin or orlistat.
However, the present data suggest that the FASN inhibitor-
induced apoptosis was independent of the activation of p53 in the
melan-a cells because pre-treatment with pifithrin-alpha (PFT)
[72] did not prevent cell death (Figure S4 B). These data are
supported by other results, indicating that p53 did not participate
in cerulenin-induced cell death in neuroblastoma, melanoma,
colon carcinoma, breast cancer, skin carcinoma and glioma tumor
cells [44,47,57,80]. Accordingly, cerulenin toxicity was higher in
p53 knockout cells than in control RKO colon carcinoma cells
[45].
To further investigate the role of FASN activity in nonmalig-
nant cells, we successfully down-regulated FASN expression in
melan-a cells using siRNA (Figure 7 A) and showed that the
Figure 6. NAC pre-incubation protects melan-a cells from
cerulenin or orlistat-induced apoptosis. Melan-a cells were pre-
incubated with 5 mM NAC for 1 h, followed by treatment with 22 mM
cerulenin for an additional 24 h (A) or 30 mM orlistat for 48 h (B). NAC
was also present during the incubations with cerulenin or orlistat.
Apoptosis was then determined by flow cytometry after Annexin V
staining. The values represent the mean 6 s.e.m of six independent
experiments. *Significantly different from the respective control at p,
0.05. #Significantly different from the respective condition in the
absence of NAC at p,0.05.
doi:10.1371/journal.pone.0101060.g006
Figure 7. FASN silencing does not induce apoptosis in melan-a
cells. Melan-a cells were either transfected with specific siRNAs (siRNA),
treated with the transfection reagent alone (mock) or maintained in
culture with equimolar concentrations of a nonspecific control oligo
(control). Cells were incubated for 48 h. FASN protein content was
determined by Western blot analysis (A), and apoptosis was estimated
by flow cytometry after Annexin V staining (B). The values represent the
mean 6 s.e.m of three independent experiments.
doi:10.1371/journal.pone.0101060.g007
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apoptosis rate remained unchanged (Figure 7 B). Additionally,
using the ESI-MS technique, we also demonstrated that the
mitochondrial FFA content and composition did not change.
Taken together, the siRNA and ESI-MS results suggest that the
FASN inhibitors act on melan-a cell mitochondria independently
of the changes in FASN activity.
To uncover the link between mitochondrial dysfunction and
apoptosis in melan-a cells treated with the FASN inhibitors, we
analyzed the mitochondrial energy-linked functions in these cells.
Both cerulenin and orlistat were able to independently inhibit the
rates of NADH-linked and succinate-supported respiration. This
result was followed by both a decrease in DYm (Figure 4 A and
B) and a significant increase in superoxide production (Figure 4
C). In agreement with these results, it was previously reported that
silencing the ACC-a (acetyl-CoA carboxylase a) and FASN genes
resulted in increased ROS production and mitochondrial
dysfunction [85].
The lack of change in both the rate of respiration supported by
the complex IV substrate TMPD (Figure 5 E) and the activity of
citrate synthase provides evidence that treatment with the FASN
inhibitors did not alter either the number of mitochondria or the
mitochondrial mass (Figure 5 F). Therefore, we hypothesize that
the decreased respiration rates are the consequence of damage to
respiratory complexes I and II. It is well known that the inhibition
of these respiratory complexes by various metabolic inhibitors,
including statins [66,86], is mediated by superoxide anion attack
on the 4Fe-4S clusters [87]. The results indicating that NAC pre-
incubation prior to treatment with FASN inhibitors significantly
protected the melan-a cells from apoptosis (Figure 6 A and B)
support the interpretation that the mitochondrial dysfunction
observed here is the consequence of superoxide attack to
respiratory complexes I and II. Additionally, it has been reported
that cell death via the activation of the intrinsic apoptosis pathway
can further stimulate ROS production and disrupt respiratory
chain complexes I and II through caspase 3, as discussed below.
During apoptosis, the mitochondrial outer membrane becomes
permeable to pro-apoptotic proteins, such as cytochrome c, which
lead to the formation of apoptosome complexes through the
interaction of caspase-9 and APAF-1 [88]. The activation of
downstream caspase-3 results in the cleavage of specific substrates
that induce DNA fragmentation, nuclear condensation, phospha-
tidylserine externalization and membrane blebbing [89–93].
Further, caspase-3 activation inhibits respiration at the levels of
complexes I and II [94]. NADH dehydrogenase Fe-S protein 1
(NDUFS1 or p 75), which is the largest subunit of complex I,
serves as a substrate for the activity of caspase-3 during apoptosis.
Cleavage by p75 directly inhibits the function of complex I,
leading to DYm collapse, ROS generation and mitochondria
damage [95].
In conclusion, the present results indicate that the FASN
inhibitors cerulenin and orlistat induced apoptotic death in the
non-tumorigenic cell line melan-a through a mechanism associ-
ated with the activation of the intrinsic apoptotic pathway,
mitochondrial oxidative stress and respiratory chain impairment,
independent of FASN inhibition.
Supporting Information
Figure S1 Cerulenin and orlistat reduce cell viability
and induce apoptosis in the HaCaT cell line. HaCaT cells
were treated with increasing concentrations of cerulenin or orlistat
for 24 or 48 h, respectively; cell viability was determined using
trypan blue (A and B) or MTT assays (C and D), and apoptosis
was determined by flow cytometry (E and F). The values represent
the mean 6 s.e.m of at least three independent experiments.
*Significantly different from the respective control at p,0.05.
(TIF)
Figure S2 The fraction of FASN protein is higher in
melan-a than HaCaT cells. Equal amounts of total protein
(40 mg) were electrophoretically separated, and the membranes
were incubated with antibodies against FASN or beta-actin.
Western blot analysis showed that the FASN content was 2.3-fold
higher in the melan-a cells than in the HaCaT cells (0.678 versus
0.294 a.u., melan-a versus HaCaT; data normalized using beta-
actin).
(TIF)
Figure S3 FASN inhibitors blocked cell cycle progres-
sion in non-tumorigenic cells. HaCaT cells (A) were treated
with 45 mM cerulenin or 300 mM orlistat for 24 or 48 h,
respectively. Then, the percentage of cells in each phase of the
cell cycle was determined by flow cytometry after PI staining.
Western blot analysis of the protein extracts prepared from
cerulenin- and orlistat-treated HaCaT cells revealed the accumu-
lation of p21WAF1/Cip1 tumor suppressor protein; the data were
normalized using beta-actin as a loading control (B). The values
represent the mean 6 s.e.m of at least five independent
experiments. *Significantly different from the respective control
at p,0.05.
(TIF)
Figure S4 FASN inhibitor-induced apoptosis is indepen-
dent of mitochondrial permeability transition or p53 in
melan-a cells. Melan-a cells were treated with 22 mM cerulenin
or 30 mM orlistat for 24 or 48 h, respectively, in the presence of
cyclosporin A (CsA, 1 mM) (A) or (B) pifithrin-alpha (PFT, 10 mM);
then, apoptosis was determined by flow cytometry after Annexin V
staining. The values represent the mean 6 s.e.m of five
independent experiments. *Significantly different from the respec-
tive control at p,0.05.
(TIF)
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